JAK2 and acute lymphoblastic leukemia: The combination of Bcl-2/Bcl-xl inhibitor ABT-737 and the type I JAKi TG101209 mediated prolonged disease regression and cure in mice bearing primary human and mouse JAK2 B-ALL and T-ALL mutant tumors.